Superior survival of young women with malignant melanoma

American Journal of Surgery

Volumn 175, Issue 6, 1998, Pages 437-445

  Kemeny, M Margaret ^a   Busch, Erna ^a   Stewart, Andrew K ^b   Menck, Herman R ^b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b AMERICAN COLLEGE OF SURGEONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER STAGING; DATA ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOSIS; PREMENOPAUSE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

AGE FACTORS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; SEX FACTORS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 0032100607     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00070-1     Document Type: Article

References (22)

1. Thorn M, Ponten F, Bergstrom R, et al. Clinical and histopathologic predictors of survival in patients with malignant melanoma a population-based study in Sweden . J Natl Cancer Inst. 86:1994;761-769.
2. Stidham KR, Johnson JL, Seigler HF. Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg. 129:1994;316-324.
3. Shaw HM, Milton GW, Farago G, et al. Endocrine influences on survival from malignant melanoma. Cancer. 42:1978;669-677.
4. Shaw JHF. Malignant melanoma in Auckland, New Zealand. Surg Gynecol Obstet. 166:1988;425-430.
5. Balch CM, Soong S, Shaw HM, et al. Analysis of prognostic factors in 8,500 patients with cutaneous melanoma. Balch CM, Houghton AN, Milton GW, et al. Cutaneous Melanoma. 2nd ed. 1992;JB Lippincott, Philadelphia.
6. Jessup JM, Steele GD, Winchester DP. Introduction. Steele GD, Jessup JM, Winchester DO, et al. National Cancer Data Base Annual Review of Patient Care. 1995;1-11 American Cancer Society, Atlanta, Ga.
7. Percy C, Van Holten V, Muir C. International Classification of Diseases for Oncology. 2nd ed. 1990;World Health Organization, Geneva.
8. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Manual for Staging Cancer. 4th ed. 1992;JB Lippincott, Philadelphia.
9. SPSS for Windows, Advanced Statistics, Release 6.1. Chicago, Ill: SPSS Inc., 1994.
10. Marubini E, Valsecchi MG. Analyzing Survival Data from Clinical Trials and Observational Studies. 1995;John Wiley & Sons, New York.
11. Shambaugh E, Young JL Jr, Zippin C, et al. Statistics and Epidemiology for Cancer Registrars. Self-Instructional Manual for Cancer Registrars. Book 7. 1995;National Institutes of Health, Bethesda, Md.
12. Lee ET. Statistical Methods for Survival Data Analysis. 1980;Wandsworth, Belmont, Calif.
13. Thorn M, Adami HO, Ringborg U, et al. Long-term survival in malignant melanoma with special reference to age and sex as prognostic factors. J Natl Cancer Inst. 79:1987;969-974.
14. Adami HO, Persson I, Hoover R, et al. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer. 44:1989;833-839.
15. Slingluff CL, Douglas RS, Vollmer RT, et al. Malignant melanoma arising during pregnancy. A study of 100 patients. Ann Surg. 211:1990;552-559.
16. Travers RL, Sober AJ, Berwick M, et al. Increased thickness of pregnancy-associated melanoma. Br J Derm. 132:1995;876-883.
17. Pianelli M, Maggiano N, Ricci R, et al. Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol. 105:1995;248-253.
18. Jones JA, Albright KD, Christen RD, et al. Synergy between Tamoxifen and Cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites. Cancer Res. 57:1997;2657-2660.
19. Beattie CW, Ronan SG, Amoss MS. Estrogens influence the natural history of sinclair swine cutaneous melanoma. Cancer Res. 51:1991;2025-2028.
20. Ladanyi A, Timar J, Bocsi J, et al. Sex-dependent liver metastasis of human melanoma lines in SCID mice. Melanoma Res. 5:(2):1995;83-86.
21. Rumke P, Kleeberg UR, MacKie RM, et al. Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group. Melanoma Res. 2:1992;153-156.
22. Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarabazine plus tamoxifen. NEJM. 327:1992;516-523.